SpineGuard Reports 16% Growth on €1.8M Revenue for 1Q16

PARIS & SAN FRANCISCO–(BUSINESS WIRE)–Regulatory News:

SpineGuard (Paris:ALSGD) (FR0011464452 – ALSGD), an innovative company that develops and markets disposable medical devices designed to make spine surgery safer, reported today that its first-quarter 2016 revenue grew by 16%, to €1.8 million.

Pierre Jérôme, CEO and co-founder of SpineGuard, said: « For the first time, we exceeded 2,000 PediGuard units sold in one quarter, and our growth continues to be strong despite an unfavorable base effect due to a large tender in the Middle-East invoiced in March 2015. In the US, by far our number-one market, we delivered a fifth consecutive quarter with over 20% cc growth. We are on track with our strategic roadmap and confident about the quarters to come. »

Global revenue in the first quarter of 2016 increased 16.0% to €1,760k, compared with €1,517k in the first quarter of 2015. At constant exchange rate (cc), the growth rate was 14.3%.

2,134 PediGuard units were sold in the first quarter of 2016 compared with 1,977 in the first quarter of 2015, including 1,134 (53%) in the United States, where revenue grew 22.6% (20.2% cc) to €1,377k compared with €1,123k.

Recent events:

Latest media article:

Becker Spine How value-based spine care shapes technology development: Key thoughts on SpineGuard (March 31)

Next financial press release: 2016 Half-year revenue: July 12, 2016

About SpineGuard®
Co-founded in 2009 in France and the USA by Pierre Jérôme and Stéphane Bette, SpineGuard’s mission is to make spine surgery safer. Its primary objective is to establish its proprietary DSG™ (Dynamic Surgical Guidance) technology as the global standard of surgical care, initially for safer screw placement in spine surgery and then in other surgeries. PediGuard®, the first device designed using DSG was co-invented by Maurice Bourlion, Ph.D., Ciaran Bolger, M.D., Ph.D., and Alain Vanquaethem, Biomedical Engineer. It is the world’s first and only handheld device capable of alerting surgeons to potential pedicular or vertebral breaches. Over 45,000 surgical procedures have been performed worldwide with PediGuard. Numerous studies published in peer-reviewed medical and scientific journals have demonstrated the multiple benefits that PediGuard delivers to patients, surgical staff and hospitals. In 2015, SpineGuard started to expand the applications of DSG into pedicle screws through partnerships with innovative surgical companies in France and the US. SpineGuard has offices in San Francisco and Paris.

For further information, visit www.spineguard.com.

Disclaimer

The SpineGuard securities may not be offered or sold in the United States as they have not been and will not be registered under the Securities Act or any United States state securities laws, and SpineGuard does not intend to make a public offer of its securities in the United States. This is an announcement and not a prospectus, and the information contained herein does and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities referred to herein in the United States in which such offer, solicitation or sale would be unlawful prior to registration or exemption from registration.